Pear Therapeutics Inc - Ordinary Shares - Class A

-0.07 (-3.91%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)237.54M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$4.24 Million
Adjusted EPS-$0.24
See more estimates
10-Day MA$2.05
50-Day MA$3.79
200-Day MA$6.16
See more pivots

Pear Therapeutics Inc - Ordinary Shares - Class A Stock, NASDAQ:PEAR

200 State Street, 13th Floor, Boston, Massachusetts 02109
United States of America
Phone: +1.617.925.7848
Number of Employees: 300


Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly.? The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. The companyâ??s lead product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Its second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway while simultaneously reviewed through the FDA's Software Precertification Pilot Program. The company was founded on December 1, 2020 and is headquartered in Boston, MA.